Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sanofi : Biden says will have enough COVID-19 vaccine for every U.S. adult by May

03/02/2021 | 09:50pm EDT
Biden speaks about the COVID-19 pandemic response at the White House in Washington

(Reuters) - The United States will have enough COVID-19 vaccine for every American adult by the end of May, President Joe Biden said on Tuesday after Merck & Co agreed to make rival Johnson & Johnson's inoculation.

The partnership between drug makers, as well as other steps the government is taking to assist J&J, will allow the company to accelerate delivery of 100 million vaccine doses by around a month, according to the U.S. Department of Health and Human Services (HHS).

"One of the things that I learned when I came into office was that Johnson & Johnson was behind in manufacturing and production," Biden said. "It simply wasn't coming fast enough. So my team has been hard at work to accelerate that effort."

He said the U.S. government had invoked the Defense Production Act to help equip two Merck plants to make the J&J vaccine.

Biden also said plants already making J&J's vaccine would step up their output, producing 24 hours a day, 7 days a week.

These actions will ultimately double J&J's U.S. ability to produce vaccines and increase its fill-finish capacity, where the product is put into vials and readied for shipping, HHS said.

"We expect this manufacturing arrangement will enhance our production capacity so that we can supply beyond our current commitments," J&J said in a statement.

Biden said he hoped that the United States would be "back to normal" at this time next year, potentially earlier.

"It depends upon if people continue, continue to be smart and understand that we still can have significant losses," he said.

Merck chief marketing officer Mike Nally said that his company was waiting on specialized equipment to begin producing the vaccine, but that the plant where it will finish J&J's vaccine and put it into vials could be operating within a few months.

"That production capacity won't yield doses most likely until the second half of this year, towards the end of the year," Nally said in an interview, explaining that there is a longer lead time for the equipment needed to make the drug substance.

Nally did not say how many doses Merck would be able to produce for J&J. He said Merck was using half the production capacity it would have used to make a billion doses of its own vaccines, but noted that every vaccine technology has distinctive production characteristics.

An increased supply of the J&J vaccine sooner would speed the U.S. vaccination effort considerably, because you can inoculate twice as many people with the same number of shots. The other two U.S.-authorized vaccines produced by Pfizer Inc with partner BioNTech and Moderna Inc both require two shots a few weeks apart.

Under its contract, J&J was supposed to deliver 12 million doses by the end of February, but had less than 4 million ready to ship when the vaccine was authorized on Saturday.

It expects to be able to deliver another 16 million doses by the end of this month - still well short of its previous commitments - but will not ship any next week. The next shipments are waiting on regulatory approval of new manufacturing operations run by its partner, contract drugmaker Catalent Inc.

Merck said on Tuesday it will also receive up to $268.8 million from the Biomedical Advanced Research and Development Authority (BARDA), a U.S. agency charged with developing drugs and vaccines. The funding is intended to help it to adapt and make available a number of its plants for COVID-19 vaccine and medicine production.

The partnership is the latest example of large drugmakers working together to help produce COVID-19 vaccines to meet global demand. Swiss drugmaker Novartis signed an agreement in January to fill vials for the Pfizer/BioNTech shot, while French drugmaker Sanofi SA will help fill and pack millions of doses of Pfizer's vaccine starting in July.

(Reporting by Manas Mishra in Bengaluru, Michael Erman in New York, Nandita Bose, Steve Holland and Susan Heavey in Washington; Editing by Caroline Humer, Jonathan Oatis, Bill Berkrot and Gerry Doyle)

By Nandita Bose and Michael Erman

© Reuters 2021
All news about SANOFI
04/16MUCINOUS CYSTIC NEOPLASM PIPELINE : Emerging Therapies and Key pharma players in..
04/16MARKET CHATTER : Sanofi Launches Its First China Research Institute
04/15Activist investor Elliott takes multibillion pound stake in GSK, FT says
04/15SANOFI  : Gets a Buy rating from UBS
04/14SANOFI  : After Setbacks, Rollout of New TB Prevention Pills to Start in Six Dis..
04/14SANOFI  : JP Morgan reiterates its Buy rating
04/13C4X DISCOVERY  : Up to EUR414 million Exclusive Worldwide Licensing Agreement wi..
04/13SWEDISH ORPHAN BIOVITRUM  : Sobi Doses First Patient In Phase 3 Trial Of Pediatr..
04/13SWEDISH ORPHAN BIOVITRUM  : First patient dosed in phase 3 XTEND-Kids study with..
04/13SANOFI  : Declares Kiadis Offer Unconditional, All Offer Conditions Now Satisfie..
More news
Sales 2021 36 956 M 44 281 M 44 281 M
Net income 2021 5 909 M 7 080 M 7 080 M
Net Debt 2021 7 285 M 8 728 M 8 728 M
P/E ratio 2021 17,9x
Yield 2021 3,86%
Capitalization 106 B 127 B 127 B
EV / Sales 2021 3,07x
EV / Sales 2022 2,81x
Nbr of Employees 99 412
Free-Float 88,7%
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 100,65 €
Last Close Price 85,01 €
Spread / Highest target 37,6%
Spread / Average Target 18,4%
Spread / Lowest Target -17,7%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Chairman
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI8.02%127 185
JOHNSON & JOHNSON3.09%427 130
ROCHE HOLDING AG0.06%289 376
PFIZER INC.2.15%215 150
NOVARTIS AG-3.32%198 528
MERCK & CO., INC.-5.29%196 100